详细信息
Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway
文献类型:期刊文献
中文题名:Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway
作者:Jinlian Wei[1];Xin Chen[1];Yongyun Li[2];Ruoxi Li[1];Keting Bao[1];Liang Liao[1];Yuqing Xie[1];Tiannuo Yang[1];Jin Zhu[1];Fei Mao[1];Shuaishuai Ni[3];Renbing Jia[2];Xiaofang Xu[2];Jian Li[1,4,5,6]
机构:[1]State Key Laboratory of Bioreactor Engineering,Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism,Frontiers Science Center for Materiobiology and Dynamic Chemistry,Shanghai Key Laboratory of New Drug Design,School of Pharmacy,East China University of Science and Technology,Shanghai 200237,China;[2]Department of Ophthalmology,Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;[3]Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;[4]Yunnan Key Laboratory of Screening and Research on Anti-pathogenic Plant Resources from West Yunnan,College of Pharmacy,Dali University,Dali 671000,China;[5]Clinical Medicine Scientific and Technical Innovation Center,Shanghai Tenth People’s Hospital,Tongji University School of Medicine,Shanghai 200092,China;[6]Key Laboratory of Tropical Biological Resources of Ministry of Education,College of Pharmacy,Hainan University,Haikou 570228,China
年份:2022
卷号:12
期号:10
起止页码:3861
中文期刊名:Acta Pharmaceutica Sinica B
外文期刊名:药学学报(英文版)
收录:CSTPCD;;Scopus;CSCD:【CSCD2021_2022】;PubMed;
基金:supported by the National Mega-project for Innovative Drugs of China(2019ZX09721001-004-003);the National Natural Science Foundation of China(82003603 and 81872747);the Innovative Research Team of High-level Local Universities in Shanghai,the National Special Fund for State Key Laboratory of Bioreactor Engineering(2060204,China);Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism(2021 Sci&Tech 03-28,China).
语种:英文
中文关键词:Conjunctival melanoma;Cucurbitacin B;Activity-based protein profiling;G2/M cell cycle;GRP78;FOXM1;KIF20A;Rare tumor
摘要:Conjunctival melanoma(CM) is a rare and fatal malignant eye tumor. In this study, we deciphered a novel anti-CM mechanism of a natural tetracyclic compound named as cucurbitacin B(CuB). We found that CuB remarkably inhibited the proliferation of CM cells including CM-AS16,CRMM1, CRMM2 and CM2005.1, without toxicity to normal cells. CuB can also induce CM cells G2/M cell cycle arrest. RNA-seq screening identified KIF20A, a key downstream effector of FOXM1 pathway, was abolished by CuB treatment. Further target identification by activity-based protein profiling chemoproteomic approach revealed that GRP78 is a potential target of CuB. Several lines of evidence demonstrated that CuB interacted with GRP78 and bound with a Kdvalue of0.11 μmol/L. Furthermore, ATPase activity evaluation showed that CuB suppressed GRP78 both in human recombinant GRP78 protein and cellular lysates. Knockdown of the GRP78 gene significantly induced the downregulation of FOXM1 and related pathway proteins including KIF20A, underlying an interesting therapeutic perspective. Finally, CuB significantly inhibited tumor progression in NCG mice without causing obvious side effects in vivo. Taken together, our current work proved that GRP78-FOXM1-KIF20A as a promising pathway for CM therapy, and the traditional medicine CuB as a candidate drug to hinder this pathway.
参考文献:
正在载入数据...
